U.S. regulators have approved a more convenient version of a blockbuster drug for treating three common blood cancers.
The Roche Groupâs Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take several hours.
On Thursday, the Food and Drug Administration approved the Swiss drugmakerâs new version, Rituxan Hycela (RIHâ-tux-en HEYEâ-cell-uh). Itâs injected in about six minutes, shortening clinic visits.
Itâs given every three weeks for ...
Share this post
← Back to Utah